Acorda Therapeutics Long-Term Debt 2011-2026 | ACOR

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Acorda Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	167 M	151 M	166 M	218 M	343 M	334 M	324 M	297 M	290 M	3.23 M	4.24 M	6.26 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
343 M	3.23 M	192 M

Quarterly Long-Term Debt Acorda Therapeutics

2024-Q1	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.85 M	171 M	167 M	163 M	159 M	155 M	151 M	147 M	144 M	141 M	138 M	138 M	138 M	138 M	193 M	193 M	193 M	193 M	319 M	319 M	319 M	319 M	309 M	309 M	309 M	309 M	299 M	299 M	299 M	299 M	290 M	290 M	290 M	290 M	288 M	14 K	258 K	344 K	493 K	659 K	493 K	493 K	1.11 M	1.11 M	1.11 M	1.11 M	1.9 M	1.9 M	1.9 M	1.9 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
319 M	14 K	158 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
AbbVie ABBV	64.5 B	$ 232.08	3.29 %	$ 411 B	USA
AbCellera Biologics ABCL	137 M	$ 3.61	0.56 %	$ 1.08 B	Canada
Abeona Therapeutics ABEO	4.4 M	$ 5.12	-1.54 %	$ 109 M	USA
Arbutus Biopharma Corporation ABUS	1.82 M	$ 4.66	-0.85 %	$ 773 M	Canada
ACADIA Pharmaceuticals ACAD	42 M	$ 24.56	-0.32 %	$ 4.07 B	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Achieve Life Sciences ACHV	6 K	$ 4.56	-3.59 %	$ 90.4 M	USA
AC Immune SA ACIU	1.81 M	$ 2.93	-1.01 %	$ 229 M	Schweiz
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	13.2 M	-	-10.17 %	$ 12.2 K	USA
Aclaris Therapeutics ACRS	1.56 M	$ 2.87	-8.31 %	$ 352 M	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Adagene ADAG	417 K	$ 2.96	-4.67 %	$ 167 M	China
ADC Therapeutics SA ADCT	6.99 M	$ 4.1	-0.73 %	$ 105 M	Schweiz
Adial Pharmaceuticals ADIL	207 K	$ 2.53	-	$ 16.4 M	USA
ADMA Biologics ADMA	69.3 M	$ 15.57	2.57 %	$ 3.71 B	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
Adaptive Biotechnologies Corporation ADPT	127 M	$ 16.02	-2.67 %	$ 2.43 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
ADiTx Therapeutics ADTX	436 K	$ 0.46	-4.63 %	$ 6.06 K	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Agenus AGEN	12.8 M	$ 3.33	-0.89 %	$ 1.19 M	USA
Agios Pharmaceuticals AGIO	21.8 M	$ 30.23	0.83 %	$ 1.75 B	USA
AIM ImmunoTech AIM	659 K	$ 0.91	-8.59 %	$ 43.8 M	USA
Akebia Therapeutics AKBA	48.2 M	$ 1.31	-0.76 %	$ 337 M	USA
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Aldeyra Therapeutics ALDX	15 M	$ 5.46	-0.73 %	$ 328 M	USA
Alector ALEC	9.32 M	$ 2.43	-5.08 %	$ 250 M	USA
Aligos Therapeutics ALGS	231 K	$ 7.03	-6.27 %	$ 452 M	USA
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Alkermes plc ALKS	63.3 M	$ 30.1	-2.05 %	$ 4.96 B	Irlanda
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Allogene Therapeutics ALLO	88.3 M	$ 2.78	1.83 %	$ 436 M	USA
AIkido Pharma AIKI	2.63 M	-	1.93 %	$ 17.4 M	USA
Alnylam Pharmaceuticals ALNY	1.01 B	$ 332.92	0.51 %	$ 43.6 B	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Altimmune ALT	1.4 M	$ 4.31	-3.36 %	$ 306 M	USA
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
ALX Oncology Holdings ALXO	9.47 M	$ 2.11	-10.21 %	$ 110 M	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Amgen AMGN	50 B	$ 388.16	2.33 %	$ 209 B	USA
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	16.6 M	-	4.14 %	$ 49.1 M	USA